Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy
- Sponsor
- National Taiwan University Hospital
- Study ID
- NCT01920984
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 25 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- intravitreal injection of 1.25 mg of bevacizumab — DRUGPatients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
Study Details
To determine the vitreous levels of fractalkine, cysteine-rich 61 (Cyr61), and VEGF in patients with PDR. Verifying that it is greater to that found in non-diabetic patients with different non-angiogenetic diseases.
Key Dates
- First listed
- Aug 13, 2013
- Start date
- Jan 31, 2005
- Status verified
- Jan 2004
- Primary completion
- Dec 31, 2006
- Completion
- Dec 31, 2006
Study Design
- Enrollment
- 100 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: pretreatment of bevacizumabPatients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy due to diabetic retinopathy.
- No Intervention: No pretreatment of bevacizumabPatients will not receive bevacizumab pretreatment before vitreous surgery.
Primary Outcome Measure
Vitreous levels of Fractalkine, Cyr61, and VEGF of patients with proliferative diabetic retinopathy [ Time Frame: 7 days ]